Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
Top Cited Papers
- 1 August 2008
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 372 (9638), 547-553
- https://doi.org/10.1016/s0140-6736(08)61236-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsNew England Journal of Medicine, 2008
- Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential HypertensionAnnals of Internal Medicine, 2008
- Assessing Kidney Function — Measured and Estimated Glomerular Filtration RateNew England Journal of Medicine, 2006
- Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetesJCI Insight, 2006
- Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2004
- Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trialsAmerican Heart Journal, 2004
- Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-AnalysisAnnals of Internal Medicine, 2003
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic IndividualsJAMA, 2001